Journal of Dermatology最新文献

{"title":"Quality of life in children with erythropoietic protoporphyria: a case–control study","authors":"Louisa G. Kluijver,&nbsp;Debby Wensink,&nbsp;Margreet A. E. M. Wagenmakers,&nbsp;Hidde H. Huidekoper,&nbsp;Peter Witters,&nbsp;Daisy Rymen,&nbsp;Janneke G. Langendonk","doi":"10.1111/1346-8138.17348","DOIUrl":"10.1111/1346-8138.17348","url":null,"abstract":"<p>Erythropoietic protoporphyria (EPP) is an inherited metabolic disease that causes painful phototoxic reactions, starting in childhood. Studies have shown a reduced quality of life (QoL) in adults with EPP, however, data on children with the disease are lacking. Since treatment for EPP is currently not registered for children, knowledge about their QoL is of crucial importance. In this prospective, case–control study, we included children from the Netherlands and Belgium diagnosed with EPP and matched to healthy controls. Previously collected EPP quality of life (EPP-QoL) data from matched adults with EPP were used. QoL scores, utilizing the Pediatric Quality of Life Inventory (PedsQL) and the disease-specific EPP-QoL, were collected. Scores range from 0 to 100, with higher scores indicating a higher QoL. Non-parametric tests were used to compare groups. A total of 15 cases, 13 matched healthy control children, and 15 matched adults with EPP were included. Children with EPP exhibited lower median scores in the PedsQL in both physical (cases: 87.5 (interquartile range [IQR] 77.7–96.1), controls: 99.2 [IQR 94.9–100.0], <i>p</i> = 0.03) and social (cases: 77.5 [IQR 69.4–86.3], controls: 97.5 [IQR 78.8–100.0], <i>p</i> = 0.04) domains compared to healthy children, although these differences were not statistically significant after correcting for multiple testing. The overall median EPP-QoL score for children was similar to adults with EPP (children: 44.4 [IQR 25.0–54.2], adults: 45.8 [IQR 25.7–68.1], <i>p</i> = 0.68). However, within the EPP-QoL subdomain on QoL, children were found to have significantly lower median scores (children: 16.7 [IQR 0.0–33.3], adults: 33.3 [IQR 33.3–62.5], <i>p</i> &lt; 0.01). In conclusion, children with EPP experience a reduced QoL compared to both healthy children and adults with EPP. Ensuring treatment availability for this patient group is crucial for improving their QoL. We advocate the inclusion of children in safety and efficacy studies, to ensure availability of treatment in the future.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 8","pages":"1068-1078"},"PeriodicalIF":2.9,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17348","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of cutaneous neurofibromas on quality of life and mental health in neurofibromatosis type 1","authors":"Brieana Dance,&nbsp;Alice Dardare,&nbsp;Jane Fleming,&nbsp;Sue-Faye Siow,&nbsp;Timothy E. Schlub,&nbsp;Hilda Crawford,&nbsp;Rebecca B. Saunderson,&nbsp;Claire Wong,&nbsp;Yemima Berman","doi":"10.1111/1346-8138.17276","DOIUrl":"10.1111/1346-8138.17276","url":null,"abstract":"<p>The skin manifestations of neurofibromatosis 1 significantly reduce health-related quality-of-life. However, data on the utility of existing surveys in capturing neurofibromatosis 1 skin treatment outcomes are lacking. This quantitative study examined the relationship between clinician-rated severity and visibility and patient-rated itch and quality-of-life (QoL) to (1) establish baseline levels of skin- and condition-specific-related QoL, itch, depression and anxiety; (2) identify patient concerns to inform the development and evaluation of skin interventions; and (3) compare the sensitivity of different QoL measures. Validated scales included Skindex-29, Dermatology Life Quality Index (DLQI), Neurofibromatosis 1-adult quality-of-life (NF1-AdQOL) questionnaire, and the Hospital Anxiety and Depression Scale (HADS). We recruited 100 participants (response rate: 95%). Of these, 42% reported itch and 23% had probable clinical anxiety. Our cohort had higher levels of anxiety and total HADS scores compared to a control population. Using multivariate regression analysis, increasing visibility significantly predicted poorer QoL using the Skindex-29, NF1-AdQOL, and DLQI (<i>p</i> &lt; 0.05); and itch significantly predicted worse QoL in Skindex-29 and NF1-AdQOL (<i>p</i> &lt; 0.05). The highest mean scoring questions in Skindex-29 and NF1-AdQOL concerned worry about worsening skin disease and embarrassment. The highest mean scoring questions in DLQI were regarding itch, pain, and embarrassment. Items asking specifically about cutaneous neurofibromas (cNF) scored higher than comparable skin-specific questions (<i>t</i>-test <i>p</i> value &lt;0.05). In summary, this study provides insights into the factors contributing to impaired QoL, anxiety, and mood in NF1 patients with cutaneous neurofibromas. Key factors identified for use in cNF measures include visibility, itch, anxiety, embarrassment, fears of worsening skin disease, and cNF-specific questions.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 8","pages":"1050-1059"},"PeriodicalIF":2.9,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17276","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reevaluating hybrid neurofibroma/schwannoma: Predominance of schwannoma features despite CD34 positivity and initial neurofibroma diagnosis","authors":"Tatsuya Katsumi,&nbsp;Ryota Hayashi,&nbsp;Shingo Takei,&nbsp;Osamu Ansai,&nbsp;Sumiko Takatsuka,&nbsp;Tatsuya Takenouchi,&nbsp;Kyota Saito,&nbsp;Kazuaki Suda,&nbsp;Kosuke Yoshihara,&nbsp;Takahiro Nagai,&nbsp;Shujiro Okuda,&nbsp;Takaya Fukumoto,&nbsp;Shin-ichi Ansai,&nbsp;Anna Nakamura,&nbsp;Koji Katsuumi,&nbsp;Takashi Ariizumi,&nbsp;Akira Ogose,&nbsp;Hiroyuki Kawashima,&nbsp;Riichiro Abe","doi":"10.1111/1346-8138.17343","DOIUrl":"10.1111/1346-8138.17343","url":null,"abstract":"<p>Schwannomas consist of both high-cellularity regions (Antoni A area) and hypocellular regions (Antoni B area) in histopathological findings. Neurofibromas characteristically consist of CD34 positive spindle cells with thin, wavy, nuclei and wavy collagen bands. Previous reports have described segments of schwannomas with neurofibroma features as hybrid tumors, although hybrid tumors were diagnosed based on partial CD34 positivity in many previous reports. On the other hand, the Antoni B area of some schwannomas was reported to be positive for CD34. Therefore, the definition of a hybrid tumor has not been clear. The objective of this study was to determine whether only CD34 positive findings in schwannomas could be used to define a hybrid tumor. In the analysis of our patient with schwannomatosis caused by a novel <i>LZTR1</i> germline mutation, part of the tumor had CD34 positive hypocellular regions. These regions contained no thin, wavy, nuclei, indicating an Antoni B area. Laser microdissection was used to investigate the genetic background and differences in molecular mechanisms between CD34 positive and CD34 negative regions. All mutations identified in CD34 positive regions were also found in CD34 negative regions. Our data could not clear the genetic background of Antoni B which was CD34 positive area. We then reviewed the pathologies of 66 sporadic schwannomas. Histopathological examinations of all schwannomas revealed the absence of thin, wavy, nuclei and wavy collagen bands, and no hybrid tumors were found in any of the cases. Ten of 66 patients were randomly selected for CD34 immunostaining and positivity was found in all cases. Our data suggest that it is difficult to distinguish schwannomas by staining for CD34 alone, as Antoni B areas can also be positive for CD34. Therefore, CD34 staining alone should not be used to diagnose hybrid tumors in patients with schwannomas.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 11","pages":"1461-1469"},"PeriodicalIF":2.9,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141507419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The treatment effect of endovascular therapy for chronic limb-threatening ischemia with systemic sclerosis","authors":"Yoshihiro Matsuda,&nbsp;Tomoko Miyake,&nbsp;Hironobu Toda,&nbsp;Kota Tachibana,&nbsp;Hayato Nomura,&nbsp;Yoji Hirai,&nbsp;Yoshio Kawakami,&nbsp;Naoya Sakoda,&nbsp;Shin Morizane","doi":"10.1111/1346-8138.17334","DOIUrl":"10.1111/1346-8138.17334","url":null,"abstract":"<p>Systemic sclerosis (SSc) is a collagen disease with immune abnormalities, vasculopathy, and fibrosis. Ca blockers and prostaglandins are used to treat peripheral circulatory disturbances. Chronic limb-threatening ischemia (CLTI) is a disease characterized by extremity ulcers, necrosis, and pain due to limb ischemia. Since only a few patients present with coexistence of CLTI and SSc, the treatment outcomes of revascularization in these cases are unknown. In this study, we evaluated the clinical characteristics and treatment outcomes of seven patients with CLTI and SSc, and 35 patients with uncomplicated CLTI who were hospitalized from 2012 to 2022. A higher proportion of patients with uncomplicated CLTI had diabetes and male. There were no significant differences in the age at which ischemic ulceration occurred, other comorbidities, or in treatments, including antimicrobial agents, revascularization and amputation, improvement of pain, and the survival time from ulcer onset between the two subgroups. EVT or amputation was performed in six or two of the seven patients with CLTI and SSc, respectively. Among those who underwent EVT, 33% (2/6) achieved epithelialization and 67% (4/6) experienced pain relief. These results suggest that the revascularization in cases with CLTI and SSc should consider factors such as infection and general condition, since revascularization improve the pain of these patients.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 8","pages":"1108-1112"},"PeriodicalIF":2.9,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17334","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bevacizumab-associated toxic epidermal necrolysis in a patient with liver cancer","authors":"Hui Fan,&nbsp;LuLu Yan,&nbsp;Yuwei Tan,&nbsp;Jianglong Feng,&nbsp;Wei Zhang","doi":"10.1111/1346-8138.17285","DOIUrl":"10.1111/1346-8138.17285","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 11","pages":"e393-e394"},"PeriodicalIF":2.9,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Target area treatment ratio of varied lesions in the cultured pure melanocyte transplantation repigmentation of vitiligo: A retrospective study","authors":"Fuquan Lin,&nbsp;Yunxia Wang,&nbsp;Yujie Zheng,&nbsp;Weisong Hong,&nbsp;Lifang Fu,&nbsp;Miaoni Zhou,&nbsp;Aie Xu","doi":"10.1111/1346-8138.17320","DOIUrl":"10.1111/1346-8138.17320","url":null,"abstract":"<p>Autologous cultured pure melanocyte transplantation (CMT) can be utilized to treat stable vitiligo cases, but clinical data are insufficient to improve its efficacy. To evaluate the influence of various factors on the therapeutic effect of CMT, this single-center retrospective study enrolled stable vitiligo patients who underwent CMT between 2009 and 2020. Univariate and multivariable analysis were used to determine the factors affecting the outcome of repigmentation. The study included 491 patients with long-term follow-up data (6–120 months). It was found that 69.7% of patients achieved an excellent re-color effect and 18.4% achieved a good re-color effect. There were statistically significant differences in pigmentation between patients with stable disease course, vitiligo type, and lesion site. Overall, a significant positive correlation between the target area treatment ratio of varied lesions and the percentage of repigmentation was found. CMT is effective and well tolerated in the treatment of stable vitiligo. Various factors, especially the target area treatment ratio of varied lesions, should be carefully assessed before using CMT. As the target area treatment ratio of varied lesions could further improve the post-operative repigmentation other than type of vitiligo. This clinic trial was approved by Hangzhou Third People's Hospital (number 2023KA015, national clinical record number MR-33-23-034502).</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 8","pages":"1060-1067"},"PeriodicalIF":2.9,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17320","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of spironolactone on skin biophysical properties in women with acne treated with oral spironolactone","authors":"Salin Kiratikanon,&nbsp;Ananya Maneenut,&nbsp;Nopadon Noppakun,&nbsp;Chanat Kumtornrut","doi":"10.1111/1346-8138.17333","DOIUrl":"10.1111/1346-8138.17333","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Spironolactone (SPL) is an effective treatment for women acne, but other effects on skin biophysical properties remain to be investigated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective<b>s</b></h3>\u0000 \u0000 <p>The aim of the current study was to explore the effects of oral SPL used to treat women acne on skin biophysical properties, including hydration, transepidermal water loss (TEWL), skin surface lipid (SSL) levels, mechanical properties, color, pH, and pore size.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Twenty-five Thai women with acne treated with oral SPL were followed for 6 months. Skin hydration, TEWL, SSL levels, mechanical properties, color, pH, and pore size of the forehead, chest, and inner arm were evaluated at baseline and 2, 4, and 6 months after treatment with oral SPL. Facial and upper back pore size were also assessed. Clinical outcomes were changes in these skin biophysical properties at each visit compared with baseline.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Skin hydration, TEWL, SSL levels, color, pH, and pore size remained stable throughout the study. Facial skin parameters at 6 months demonstrated the following changes: hydration levels, 7.60 (95% confidence interval [CI], −59.74 to 74.94); TEWL, −2.36 (95% CI, −5.77 to 1.06); L* value, 0.51 (95% CI, −0.70 to 1.72); individual typology angle, 1.65 (95% CI −2.27 to 5.57); pH, 0.01 (95% CI −0.43 to 0.46); pore size, −0.24 (95% CI, −1.21 to 0.73); and SSL levels, 7.60 (95% CI −59.74 to 74.94). Improvement of facial mechanical properties was observed. R0 (indicating skin tightness) and R1 (indicating elasticity) showed significant decreases (−0.076 [95% CI, −0.141 to −0.010] and −0.016 [95% CI, −0.033 to −0.001]). R3 and R4 (representing tiring effects) were also improved (−0.091 [95% CI, −0.158 to −0.025] and −0.022 [95% CI, −0.044 to −0.001]). Parameters in the truncal and inner arm areas remained stable, except for skin elasticity and tiring effects, which exhibited a similar trend of improvement as the facial area. The changes were notable as early as 4 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Oral SPL used for acne did not impair the skin barrier. Moreover, the skin mechanical properties were improved at 4 to 6 months.</p>\u0000 </section>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 11","pages":"1454-1460"},"PeriodicalIF":2.9,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin colonization by Staphylococcus aureus in hemodialysis patients with pruritus and the effect of Staphylococcus aureus-secreted α-toxin on filaggrin expression","authors":"Yen-Yu Tsai,&nbsp;Ying-Jung Chen,&nbsp;Long-Sen Chang,&nbsp;Cheng-Ching Wu","doi":"10.1111/1346-8138.17326","DOIUrl":"10.1111/1346-8138.17326","url":null,"abstract":"<p><i>Staphylococcus aureus</i> (<i>S. aureus</i>) commonly reside on human skin in residents in long-term care facilities, yet its colonization and impact on the skin of hemodialysis (HD) patients have yet to be studied. The aim of the present study was to investigate the colonization of <i>S. aureus</i> on the skin of pruritic and non-pruritic HD patients, and the influence of <i>S. aureus</i> and <i>S. aureus</i>-secreted α-toxin on skin barrier function-related protein expression. In this study, a higher relative <i>S. aureus</i> count in pruritic HD patients compared to non-pruritic HD patients and healthy subjects were revealed by real-time polymerase chain reaction. <i>S. aureus</i> and α-toxin decreased mRNA and protein expression levels of aryl hydrocarbon receptor (AHR), ovo-like transcriptional repressor 1 (OVOL1), and filaggrin (FLG) in keratinocytes. In addition, anti-alpha-hemolysin (anti-hla) was used as an α-toxin neutralizer, and it successfully abrogated <i>S. aureus</i>-induced AHR, OVOL1, and FLG mRNA and protein expression downregulation. Mechanistically, α-toxin could decrease FLG activity by preventing the recruitment of AHR to the FLG promoter region. In conclusion, pruritic HD patients had higher <i>S. aureus</i> colonization, with <i>S. aureus</i>-secreted α-toxin suppressing FLG expression through the AHR-FLG axis.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 10","pages":"1318-1328"},"PeriodicalIF":2.9,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative study of efficacy and safety: Biosimilar rituximab versus originator rituximab in the treatment of pemphigus","authors":"Sang Heon Shin,&nbsp;Jae Yeon Kim,&nbsp;Soo-Chan Kim,&nbsp;Jong Hoon Kim","doi":"10.1111/1346-8138.17329","DOIUrl":"10.1111/1346-8138.17329","url":null,"abstract":"<p>Rituximab is a monoclonal antibody that targets CD20 antigen in B cells. For pemphigus, rituximab has been highly effective in steroid-sparing therapy for moderate to severe cases. Originator rituximab has demonstrated favorable treatment effects in patients with pemphigus, but its high cost remains a challenge. Biosimilar rituximab is expected to offer a potential solution. However, it is required for the comparative study of efficacy and safety between biosimilar and originator because all biosimilars may not be identical to the originator. In this study, we compared the treatment effects and safety of biosimilar (Truxima) and originator (MabThera) rituximab in patients with pemphigus. A final cohort of 52 patients in the MabThera group and 72 patients in the Truxima group was enrolled. Except for the intravenous immunoglobulin administration rate, there were no differences in baseline characteristics between the two groups, and for the purpose of comparing efficacy, investigations into time to complete remission, total steroid intake to complete remission, and total steroid intake for 6 months following rituximab treatment revealed no significant differences between the two groups. Truxima can be considered a relatively affordable alternative treatment option for pemphigus, offering cost-effectiveness to patients who are indicated for the treatment with MabThera.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 8","pages":"1104-1107"},"PeriodicalIF":2.9,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.17329","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lack of IL36RN sequence variation in three Chinese patients with subcorneal pustular dermatoses","authors":"Chang-Yu Hsieh,&nbsp;Tsen-Fang Tsai","doi":"10.1111/1346-8138.17336","DOIUrl":"10.1111/1346-8138.17336","url":null,"abstract":"","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"51 11","pages":"e412-e413"},"PeriodicalIF":2.9,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}